Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, OSE Immunotherapeutics's Enterprise Value is $103.05 Mil.
OSE Immunotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-39.52 Mil. Therefore, OSE Immunotherapeutics's EV-to-OCF for today is -2.61.
The historical rank and industry rank for OSE Immunotherapeutics's EV-to-OCF or its related term are showing as below:
ORPOF'
s EV-to-OCF Range Over the Past 10 Years
Min: -18.87 Med: -4.57 Max: 123.72
Current: -2.69
During the past 13 years, the highest EV-to-OCF of OSE Immunotherapeutics was 123.72. The lowest was -18.87. And the median was -4.57.
ORPOF's EV-to-OCF is ranked worse than 54.55% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs ORPOF: -2.69
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
OSE Immunotherapeutics (OTCPK:ORPOF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
OSE Immunotherapeutics's PE Ratio (TTM) for today is calculated as:
OSE Immunotherapeutics's share price for today is $4.43.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OSE Immunotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.991.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OSE Immunotherapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OSE Immunotherapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where OSE Immunotherapeutics's EV-to-OCF falls into.
OSE Immunotherapeutics's current Enterprise Value is $103.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OSE Immunotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-39.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSE Immunotherapeutics (ORPOF) has a EV-to-OCF of -2.61 as of Aug. 11, 2026. According to the industry distribution chart, OSE Immunotherapeutics ranks #767 out of 1406 companies in the Biotechnology industry, placing it in the top 54.6%.
Is OSE Immunotherapeutics' EV-to-OCF too high?
OSE Immunotherapeutics' current EV-to-OCF is -2.61. Based on the distribution chart, OSE Immunotherapeutics ranks #767 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OSE Immunotherapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #767 out of 1406 companies for EV-to-OCF. This places OSE Immunotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. OSE Immunotherapeutics's current EV-to-OCF is -2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
OSE Immunotherapeutics (ORPOF) has a current EV-to-OCF of -2.61. The stock's GF Value™ is $1.93, compared to a current price of $4.43 — trading 129.5% above its estimated fair value. The current EV-to-OCF is -2.61. OSE Immunotherapeutics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current EV-to-OCF is -2.61 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?
Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued.
The current stock price of $4.43 is trading 129.5% above its estimated GF Value™ of $1.93.
Key valuation signals for ORPOF:
EV-to-OCF: -2.61
GF Value™: $1.93 vs. price of $4.43 (129.5% above fair value)
No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
33GF Score
Get the complete analysis for ORPOF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPOF has been successfully added to your 
